Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Belani, C. P.
Ramalingam, S.
Schreeder, M.
Steis, R.
Guidice, R.
Marshland, T.
Butler, B.
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[2] Clearview Canc Inst, Huntsville, AL USA
[3] Atlanta Canc Care, Roswell, GA USA
[4] New Mexico Oncol Hematol Consultants, Albuquerque, NM USA
[5] Integrated Community Oncol Network, Orange Pk, FL USA
[6] Int Oncol Network, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7643
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] A phase II trial of biweekly docetaxel combined with carboplatin for patients with advanced non-small cell lung cancer
    Ishimoto, O
    Sugawara, S
    Inoue, A
    Ishida, T
    Koinumaru, S
    Hasegawa, Y
    Suzuki, T
    Miki, H
    Saijo, Y
    Nukiwa, T
    [J]. LUNG CANCER, 2005, 49 : S391 - S391
  • [33] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer
    Giannakakis, T
    Kakolyris, S
    Theodoropoulos, E
    Kouroussis, C
    Michailakis, E
    Papadouris, S
    Tsitoura, M
    Kalbakis, K
    Souglakos, J
    Agelaki, S
    Vardakis, N
    Georgoulias, V
    [J]. ANTICANCER RESEARCH, 2002, 22 (6B) : 3743 - 3748
  • [35] Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study
    Kortsik, C
    Albrecht, P
    Elmer, A
    [J]. LUNG CANCER, 2003, 40 (01) : 85 - 90
  • [36] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    [J]. LUNG CANCER, 2005, 49 : S272 - S272
  • [37] ACTIVITY OF PATUPILONE IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Zatloukal, P.
    Mellemgaard, A.
    Sanchez, J. M.
    Perry, M. C.
    Hamm, J. T.
    Van Meerbeeck, J.
    DeLeo, J. J.
    Gao, B.
    Johri, A. R.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 109 - 109
  • [38] Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non small cell lung cancer (NSCLC).
    Chahine, GY
    Nasr, FL
    Kattan, JG
    Farhat, FS
    El Seoudi, ME
    Bachour, M
    Moukadem, WT
    Younes, FC
    Ghosn, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [39] Vinorelbine (VNR)-cisplatin (CDDP)-carboplatin (CBDCA) combination in locally advanced or metastatic non-small cell lung cancer (NSCLC) plus phase II study
    Zylberait, D
    Charvolin, P
    Bernabeu, L
    Dumont, P
    Fallouh, H
    Biville, F
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 97 - 98
  • [40] Cetuximab treatment in combination with gemcitabine/docetaxel or carboplatin/gemcitabine for chemonaive patients with advanced non-small cell lung cancer (NSCLC): Report on toxicity data from the ongoing Phase II/III GemTax IV study
    Pilz, L. R.
    Schmid-Bindert, G.
    Cicenas, S.
    Eschbach, C.
    Kollmeier, J.
    Kortsik, C.
    Schumann, C.
    Serke, M.
    Steins, M.
    Manegold, C.
    [J]. ONKOLOGIE, 2010, 33 : 9 - 10
12345